Bergithe Eikeland Oftedal

Position

Researcher

Affiliation

Research

I am a molecular biologist working in the field of immunogenetics focusing on endocrine autoimmune disease. Since my dissertation in 2012 at the University of Bergen I continued as a post-Doc with a one-year stay with Professor Hamish Scott at the University of Adelaide working with genetics. I was further awarded a mobility grant from the Norwegian Research council spending two years with Professor Georg Holländer at the University of Oxford working with T cell development in the thymus. Since 2019 I have been employed as a senior researcher in the KG Jebsen Centre for Autoimmune Diseases, and I was recently awarded the prestigious Excellence Emerging Investigator grant from the Novo Nordic foundation, starting January 2022. My long-term goal is to characterise genetic and molecular mechanisms of gene regulation within the adaptive immune system that are crucial for the development of tolerant T cells and B cells and combine this knowledge in multivariant disease models to better predict the onset of autoimmune tissue destruction. In addition, I am ambitious to extend my international network with the possibility for long-term collaborations.

Outreach

2024 (upcoming): 

Invited speaker at the 21st Biennial Meeting of the European Society for Immunodeficiencies (ESID), Marseille, France, 16.-19. October, 2024

 

2022: 

Invited speaker at European Congress of Endocrinology (ECE) 2022, 21–24 May 2022 in Milan Italy

Invited speaker at the 20th Biennial Meeting of the European Society for Immunodeficiencies (ESID), Gothenburg, Sweden, 12-15 October, 2022.

2016:    

Invited speaker, 12th Annual Symposium on Primary Immunodeficiency Diseases, California, USA

Selected speaker at the 43rd Scandinavian Society for Immunology meeting, Turku, Finland.

       

2015

Selected speaker at The Thymus Meeting 2015, Venice, Italy

Invited speaker at the Norwegian Immunological Society annual meeting

Publications
Academic article
Academic literature review
Academic chapter/article/Conference paper
Doctoral dissertation
Poster
Abstract
Masters thesis

See a complete overview of publications in Cristin.

Selected publications:

2023:

 

36. A partial form of AIRE deficiency underlies a mild form of Autoimmune Polyendocrine Syndrome Type 1.

Oftedal BE, Berger AH, Bruserud Ø, Goldfarb Y, Sulen A, Breivik L, Hellesen A, Ben-Dor S, Haffner-Krausz R , Knappskog PM, Johansson S, Wolff ASB, Bratland E, Abramson J, Husebye ES.

J Clin Invest. 2023 Nov 1;133(21):e169704. doi: 10.1172/JCI169704.

 

35. Regulatory T cells in autoimmune primary adrenal insufficiency.

Sjøgren T, Bjune JI, Husebye ES, Oftedal BE, Wolff ASB.

Clin Exp Immunol. 2023 Aug 14: uxad087. doi: 10.1093/cei/uxad087. Online ahead of print.

 

34. Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies.

Wolff ASB, Hansen L, Grytaas MA, Oftedal BE, Breivik L, Zhou F, Hufthammer KO, Sjøgren T, Olofsson JS, Trieu MC, Meager A, Jørgensen AP, Lima K, Greve-Isdahl Mohn K, Langeland N, Cox RJ, Husebye ES.

iScience. 2023 Jul 21;26(7):107084. doi: 10.1016/j.isci.2023.107084. Epub 2023 Jun 9.

 

33. Dominant-negative heterozygous mutations in AIRE confer diverse autoimmune phenotypes.

Oftedal BE, Assing K, Baris S, Safgren SL, Johansen IS, Jakobsen MA, Babovic-Vuksanovic D, Agre K, Klee EW, Majcic E, Ferré EMN, Schmitt MM, DiMaggio T, Rosen LB, Rahman MO, Chrysis D, Giannakopoulos A, Garcia MT, González-Granado LI, Stanley K, Galant-Swafford J, Suwannarat P, Meyts I, Lionakis MS, Husebye ES.

iScience. 2023 May 5;26(6):106818. doi: 10.1016/j.isci.2023.106818. eCollection 2023 Jun 16.

 

32. Systemic interferon type I and B cell responses are impaired in autoimmune polyendocrine syndrome type 1.

Oftedal BE, Delaleu N, Dolan D, Meager A, Husebye ES, Wolff ASB.

FEBS Lett. 2023 Apr 13. doi: 10.1002/1873-3468.14625. Online ahead of print. PMID: 37052889

 

31. Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.

Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, Parent A, Miao B, Disse E, Cugnet-Anceau C, Dalle S, Orlova E, Frolova E, Alba D, Michels A, Oftedal BE, Lionakis MS, Husebye ES, Agarwal AK, Li X, Zhu C, Li Q, Oral E, Brown R, Anderson MS, Garg A, DeRisi JL.

Diabetes. 2023 Jan 1;72(1):59-70. doi: 10.2337/db21-1172.PMID: 35709010

 

 

2022:

30. Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies.

Sjøgren T, Bratland E, Røyrvik EC, Grytaas MA, Benneche A, Knappskog PM, Kämpe O, Oftedal BE, Husebye ES, Wolff ASB.

J Autoimmun. 2022 Dec;133:102917. doi: 10.1016/j.jaut.2022.102917. Epub 2022 Sep 30. PMID: 36191466

 

29. Extrathymic expression of Aire modulates the induction of effective TH17 cell-mediated immune response to Candida albicans.

J Dobeš, O Ben-Nun, A Binyamin, L Stoler-Barak, BE Oftedal, Y Goldfarb, N Kadouri, Y Gruper, T Givony, I Zalayat, K Kováčová, H Böhmová, E Valter, Z Shulman, D Filipp, ES Husebye,  J Abramson

Nat Immunol. 2022 Jul;23(7):1098-1108. doi: 10.1038/s41590-022-01247-6. Epub 2022 Jun 27.

PMID: 35761088

 

2021:

28. Transcriptional Changes in Regulatory T Cells from Patients With Autoimmune Polyendocrine Syndrome Type 1 Suggest Functional Impairment of Lipid Metabolism and Gut Homing.

Berger AH, Bratland E, Sjøgren T, Heimli M, Tyssedal T, Bruserud Ø, Johansson S, Husebye ES, Oftedal BE, Wolff ASB.

Front Immunol. 2021 Aug 30;12:722860. doi: 10.3389/fimmu.2021.722860. eCollection 2021.

 

27. Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation

Y. Goldfarb, T. Givony, N. Kadouri, J. Dobeš, C. Peligero-Cruz, I. Zalayat, G. Damari, B. Dassa, S. Ben-Dor, Y. Gruper, BE. Oftedal, E. Bratland, MM. Erichsen, A. Berger, A. Avin, S. Nevo, U. Haljasorg, Y. Kuperman, A. Ulman, R. Haffner-Krausz, Z. Porat, U. Atasoy, D. Leshkowitz, ES. Husebye, J. Abramson

J Exp Med. 2021 Nov 1;218(11):e20201076. doi: 10.1084/jem.20201076. Epub 2021 Sep 3.

 

26. The chaperonin CCT8 controls proteostasis essential for T cell maturation, selection, and function

BE Oftedal, S Maio, A Händel, MPJ White, D Howie, S Davis, N Prevot, IA Rota, ME Deadman, BM Kessler, R Fischer, NS Trede, E Sezgin, RM Maizels, GA Holländer

Nature Communications Biology, Commun. Biol 4, 681 (2021). https://doi.org/10.1038/s42003-021-02203-0

 

25. The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease

ASB Wolff, L Breivik, KO Hufthammer, MA Grytaas, E Bratland, ES Husebye, and BE Oftedal

The European Journal of Endocrinology, DOI: https://doi.org/10.1530/EJE-20-1268, Volume/Issue: Volume 184: Issue 4, Page Range: 607–615

 

24. GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility.

D Eriksson, EC Røyrvik, M Aranda-Guillén, AH Berger, N Landegren, HA Alvarez, Å Hallgren, M Grytaas, S Ström, E Bratland, I Botusan, BE Oftedal ,…, S Johansson, O Kämpe, ES Husebye.

Nat Commun. 2021 Feb 11;12(1):959. doi: 10.1038/s41467-021-21015-8.

 

2019

23. Coexistence of Congenital Adrenal Hyperplasia and Autoimmune Addison's Disease.

Aslaksen S, Methlie P, Vigeland MD, Jøssang DE, Wolff AB, Sheng Y, Oftedal BE, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

Front Endocrinol (Lausanne). 2019 Sep 27;10:648. doi: 10.3389/fendo.2019.00648.

 

22. Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease.

Aslaksen S, Wolff AB, Vigeland MD, Breivik L, Sheng Y, Oftedal BE, Artaza H, Skinningsrud B, Undlien DE, Selmer KK, Husebye ES, Bratland E.

J Transl Autoimmun. 2019 May 28;1:100005. doi: 10.1016/j.jtauto.2019.100005.

 

2018

21. 21-hydroxylase autoantibodies are more prevalent in Turner syndrome but without an association to the autoimmune polyendocrine syndrome type I.

Berglund A, Cleemann L, Oftedal BE, Holm K, Husebye ES, Gravholt CH.

Clin Exp Immunol. 2018 Oct 29. doi: 10.1111/cei.13231. PMID: 30372540

 

20.Oral microbiota in autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Siddiqui H, Marthinussen MC, Chen T, Jonsson R, Oftedal BE, Olsen I, Husebye ES, Wolff AB.

J Oral Microbiol. 2018 Feb 26;10(1):1442986. doi: 10.1080/20002297.2018.1442986. PMID: 29503707

 

2017

19. Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune

Polyendocrine Syndrome Type 1.

Bruserud Ø, Bratland E, Hellesen A, Delaleu N, Reikvam H, Oftedal BE, Wolff ASB.

Front Immunol. 2017 Sep 1;8:1074. doi: 10.3389/fimmu.2017.01074. eCollection 2017.

PMID: 28919897

 

18. Salivary gland dysfunction in patients with autoimmune polyendocrine syndrome type I

BE Oftedal, M Cuida, MM Erichsen, M Tveiterås, A Østre, D Hammenfors, M Johnsson, K Kisand, R Klein, R Jonsson, ASB Wolff.

Autoimmunity. 2017 Jun;50(4):211-222. doi: 10.1080/08916934.2017.1344972. Epub 2017 Jul 7.

PMID: 28686485

 

17. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type-1.

EM Orlova, LS Sozaeva, MA Kareva, BE Oftedal, ASB Wolff, L Breivik, EY Zakharova, O Kämpe, PM Knappskog, VA Peterkova, ES Husebye. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3546-3556. doi: 10.1210/jc.2017-00139. PMID: 28911151

 

16. T cell receptor assessment in autoimmune disease requires access to the most adjacent immunologically active organ

Oftedal, B.E., Lundgren, B.A., Hamm, D., Finstermeier, K., Gan, P.Y., Holdsworth, S.R., Hahn, C.N., Schreiber, A.W., and Scott, H.S.

J Autoimmun. 2017 Mar 15. pii: S0896-8411(16)30344-4. doi: 10.1016/j.jaut.2017.03.002. [Epub ahead of print]. PMID: 28318808

 

2016

15. A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans

Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, Pearce SH, Mitchell AL.

J Clin Endocrinol Metab. 2016 Nov;101(11):3865-3869. Epub 2016 Sep 28. PMID: 27680876

 

14. A longitudinal follow-up of Autoimmune polyendocrine syndrome type 1.

Bruserud Ø, Oftedal BE, Landegren N, Erichsen M, Bratland E, Lima K, Jørgensen AP, Myhre AG, Svartberg J, Fougner KJ, Bakke Å, Nedrebø BG, Mella B, Breivik L, Viken MK, Knappskog PM, Marthinussen MC, Løvås K, Kämpe O, Wolff AB, Husebye ES.

J Clin Endocrinol Metab. 2016 Jun 2:jc20161821. [Epub ahead of print] PMID: 27253668

 

13. Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases

BE Oftedal, A Hellesen, MM Erichsen, E Bratland, A Vardi, J Perheentupa, EH Kemp, T Fiskerstrand, MK Viken, AP Weetman, SJ Fleishman, S Banka, WG Newman, WAC Sewell, LS Sozaeva, T Zayats, K Haugarvoll, EM Orlova, J Haavik, S Johansson, PM Knappskog, K Løvås, ASB Wolff, J Abramson, Eystein S. Husebye

Immunity. 2015 Jun 16;42(6):1185-96. doi: 10.1016/j.immuni.2015.04.021. PMID: 26084028

Impact factor: 24.1

 

2015

12. Revealing Missing Human Protein Isoforms Based on Ab Initio Prediction, RNA-seq and Proteomics

Hu, Z.-Q., Scott, H.S., Qin, G.-G., Zheng, G.-Y., Chu, X., Xie, L., Adelson, D.L., Oftedal, B.E.,

Venugopal, P., Babic, M., Hahn, C.N., Bing Zhang, B., Wang, X.-J., Nan Li, N., and Wei, C.-C.

SCIENTIFIC REPORTS 2015 Volume: 5, Article Number: 10940

 

11. 8q13.1-q13.2 Deletion Associated With Inferior Cerebellar Vermian Hypoplasia and Digital Anomalies: A New Syndrome?

Mordaunt D, Oftedal BE, Scott HS, Coates D, Barnett C

Pediatr Neurol. 2015 Feb;52(2):230-4.e1. doi: 10.1016/j.pediatrneurol.2014.09.002. PMID: 25693585

 

2014

10. Clinical and Serologic Parallels to APS-I in Patients with Thymomas and Autoantigen

Transcripts in Their Tumors.

Wolff ASB, Kärner J,Owe JF, Oftedal BE, Gilhus NE. Erichsen MM, Kämpe E,‖ Meager A, Peterson

P, Kisand K, Willcox N, Husebye ES

J Immunol. 2014 Oct 15;193(8):3880-90. doi: 10.4049/jimmunol.1401068. PMID: 25230752

 

9. ARMC5 MUTATIONS ARE COMMON IN FAMILIAL BILATERAL MACRONODULAR ADRENAL

HYPERPLASIA.

Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal BE, Cutfield R,

Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB, Torpy DJ, Scott HS.

J Clin Endocrinol Metab. 2014 Jun 6:jc20141265. PMID:24905064

Citations: 36 (webofknowledge.com)

 

8. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.

Breivik L, Oftedal BE, Bøe Wolff AS, Bratland E, Orlova EM, Husebye ES.

Clin Immunol. 2014 Jul;153(1):220-7. doi: 10.1016/j.clim.2014.04.013. Epub 2014 May 2.

 

2013

7. Anti-Cytokine Autoantibodies Preceding Onset of Autoimmune Polyendocrine Syndrome Type I Features in Early Childhood.

Wolff AS, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BE, Kisand K, Oláh E, Meloni A, Myhre

AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A.

J Clin Immunol. 2013 Oct 26. [Epub ahead of print

 

2011

6. Radioligand-Binding Assay Reveals Distinct Autoantibody Preferences for Type I Interferons in APS I and Myasthenia Gravis Subgroups.

Hapnes L, Willcox N, Oftedal BE, Owe JF, Gilhus NE, Meager A, Husebye ES, Wolff AS.

J Clin Immunol. 2011 Nov 30. [Epub ahead of print] PMID: 22127461

 

5. Measuring autoantibodies against IL-17F and IL-22 in autoimmune polyendocrine syndrome type I by radioligand binding assay using fusion proteins.

Oftedal BE, Kämpe O, Meager A, Ahlgren KM, Lobell A, Husebye ES, Wolff AS.

Scand J Immunol. 2011 Apr 28. [Epub ahead of print] PMID:21535082

 

2010

4. Flow cytometry study of blood cell subtypes reflects autoimmune and inflammatory processes in

autoimmune polyendocrine syndrome type I.

Wolff AS, Oftedal BE, Kisand K, Ersvaer E, Lima K, Husebye ES.

Scand J Immunol. 2010 Jun;71(6):459-67. PMID: 20500699

Citations: 24 (webofknowledge.com)

 

2008

3. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune

polyendocrine syndrome type I.

Oftedal BE, Wolff AS, Bratland E, Kämpe O, Perheentupa J, Myhre AG, Meager A, Purushothaman R, Ten S, Husebye ES.

Clin Immunol. 2008 Oct;129(1):163-9. Epub 2008 Aug 16.PMID: 18708298

 

2. AIRE variations in Addison's disease and autoimmune polyendocrine syndromes (APS): partial gene

deletions contribute to APS I.

Bøe Wolff AS, Oftedal B, Johansson S, Bruland O, Løvås K, Meager A, Pedersen C, Husebye ES,

Knappskog PM.

Genes Immun. 2008 Mar;9(2):130-6. Epub 2008 Jan 17.PMID: 18200029

Projects

2022-2027           “21-Hydroxylase reactive B cells and their immunotherapeutic potential in autoimmune Addison’s disease”. Funded by the Novo Nordic Fundation. 10 000 000 DKK. Oftedal is the project leader.

2021-2024           “Will B-cell tell the tales? Autoimmune B cells in autoimmune Addison’s disease”. Funded by the Regional Health Authorities. 3 000 000 NOK, Oftedal is the project leader.

2017-2021          “KG Jebsen center for autoimmune disorders”. A national centre established in Bergen, where Oftedal is a principal investigator. Funded by KG Jebsen, 18 000 000.

2017-2020          “Identification of novel monogenic autoimmune syndromes”. Partners are Husebye, Bratland and Wolff. Funded by Norwegian Research Council, 4 000 000 NOK.

2016-2019          “New perspectives on regulation of peripheral tissue antigen expression within the thymus”. Oftedal is the project leader. Partners are Georg Holländer and Eystein Husebye. Funded by the Norwegian Research Council. 3 328 000 NOK